Ann: Trading Halt, page-56

Positive results in CelGro® nerve repair study
● New clinical data 24-months after treatment shows nerve repair with CelGro® resulted in long
term, predictable and consistent restoration of arm and hand function
● All quadriplegic patients regained voluntary movement of impaired or paralysed upper limbs
within 12 months
● Patient enrolment is now complete involving repair of 35 nerves (19 patients)
● Progressing regulatory program in the US
Perth, Australia; 20 November 2020: Regenerative medicine company Orthocell Limited (ASX:OCC,
“Orthocell” or the “Company”) is pleased to announce patient enrolment for the CelGro® nerve
regeneration trial is now complete, which has to date included the repair of 35 nerves in 19 patients.
Positive long term clinical data shows nerve repair with CelGro® results in predictable and consistent
restoration of upper limb function